Lawmakers are currently divided over the extension of Obamacare subsidies, especially as the government shutdown continues. While proponents argue these taxpayer-funded subsidies help mitigate the rising costs of healthcare, others believe they merely conceal the underlying issues, which many attribute to Obamacare itself.
Congress is at a crossroads. We can either keep pushing taxpayers into a flawed and unaffordable healthcare system, or we could address the foundational problems that are escalating costs.
Some critics argue that Obamacare was fundamentally flawed from the start, trading real insurance for political expedience. Without continuing the enhanced subsidies introduced during the pandemic, there’s a real risk we could spiral into a “death spiral.” This could happen if young, healthy individuals withdraw from the system, leading to a smaller, sicker pool and consequently, higher premiums.
Even with stronger subsidies, there’s a likelihood that premiums will keep rising, necessitating even more subsidies to maintain the system. Democrats may start looking to their usual targets, such as pharmaceutical companies and the wealthy, to cover these costs.
On the other hand, Republicans are advocating for reforms aimed at lowering healthcare costs, making it more affordable for everyone, and easing the taxpayer burden. Here are some proposals.
Misinformation and criminal activities within Medicare and Medicaid result in significant waste of taxpayer money. Organized crime makes it alarmingly easy to commit fraud. Recently, eleven individuals tied to a Russian-based criminal organization were arrested for allegedly orchestrating a multibillion-dollar healthcare fraud scheme. This group is accused of defrauding Medicare and private insurance companies, totaling over $10.6 billion in fraudulent claims.
In another incident, five individuals from a Pakistani organization reportedly employed artificial intelligence to impersonate Medicare beneficiaries, affecting about 1,000 people and resulting in fraudulent claims worth around $703 million. These cases represent just a fraction of the ongoing scam epidemic.
The Trump Justice Department took significant action to confront these fraudsters and curb this widespread issue. By tackling this crime effectively, substantial savings for taxpayers could be achieved, but it requires persistent enforcement.
Another concern is that legal loopholes are further escalating costs. Hospitals exploit discrepancies in Medicare reimbursements for the same service, depending on the location of care. Under current regulations, hospitals receive reimbursements that are significantly higher than those of independent clinics. This discrepancy leads to inflated costs that were originally intended to cover hospital overhead.
Many hospitals are acquiring private practices and rebranding them as “hospital outpatient departments.” This strategy allows them to bill at hospital rates despite the fact that care quality remains unchanged. Such practices prioritize consolidation over competitive pricing.
A practical reform could be to establish site-neutral payment policies, meaning that the cost for the same service would be consistent, regardless of where the service is performed. The Congressional Budget Office estimates that adjusting payments for only one category of drug management services could yield savings of about $4 billion over ten years, while more comprehensive reforms could save roughly $100 billion.
Additionally, repealing the Biden administration’s regulatory measures on pharmaceutical companies, particularly the so-called drug price negotiation initiatives included in the Inflation Control Act, might further help control costs and encourage innovation within the industry.
A more meaningful approach to managing high drug prices could involve bipartisan reforms aimed at the role of pharmacy benefit managers, who are positioned as intermediaries in the drug distribution process. These middlemen assert that they lower drug prices, yet they profit handsomely, often to the detriment of consumers. Some pharmaceutical companies have even started selling certain medications directly to consumers, bypassing intermediaries and thereby reducing prices by about half.
Crucially, we need to reform insurance. Consumers ought to have the freedom to select health insurance plans that best fit their needs. Before Obamacare, various insurance companies offered limited benefit plans that were both affordable and popular among younger demographics. It’s essential for Congress to eliminate the restrictions imposed by Obamacare and reactivate competitive insurance markets.
There’s also a proactive proposal for a health savings account (HSA), enabling employers or individuals to fund health expenses tax-free. This would empower consumers to choose the insurance that suits them best or to directly cover healthcare costs. The intention is to foster a market atmosphere where consumers are incentivized to seek out value.
Some Republicans are contemplating their own plan rather than just prolonging Obamacare subsidies. The solution doesn’t necessarily require dismantling or defunding Obamacare; it’s about revitalizing the insurance and drug markets to truly serve consumer needs and ultimately reduce healthcare spending.
Merrill Matthews is the co-author of *On the Edge: America Faces the Entitlements Cliff.*
